Tags

Type your tag names separated by a space and hit enter

Hydroxyurea therapy associated with declining serum levels of magnesium in children with sickle cell anemia.
J Pediatr 2002; 140(5):565-9JPed

Abstract

OBJECTIVE

To obtain quantitative serum levels of total and ionized magnesium (Mg(2+)) in children with homozygous sickle cell anemia (SCA) undergoing therapy with hydroxyurea.

STUDY DESIGN

Five children, ages 11 to 14 years with homozygous SCA, were enrolled in a dose-escalating trial of hydroxyurea over an 18-month period. Serum levels of total and ionized magnesium together with ionized K(+), Na(+), and Ca(2+) were measured before hydroxyurea and every 6 months during hydroxyurea therapy.

RESULTS

Before treatment, 4 of the 5 patients had low or below-normal serum concentrations of Mg(2+) (normal range, 0.51-0.67 mmol/L). All 5 became Mg(2+)-deficient during hydroxyurea therapy, with no indication of recovery until after 12 to 18 months of drug administration (P <.05). Similar changes were noted for total magnesium concentrations. Mean serum levels of K(+), Na(+), and Ca(2+) remained consistently within normal ranges.

CONCLUSIONS

These findings warrant a controlled study of the effects of magnesium supplementation in patients with SCA receiving hydroxyurea. Potentially, such therapy could alleviate or prevent vaso-occlusive crises.

Authors+Show Affiliations

Division of Hematology-Oncology, Columbus Children's Hospital and Ohio State University, 43205, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Clinical Trial, Phase II
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

12032523

Citation

Altura, Rachel A., et al. "Hydroxyurea Therapy Associated With Declining Serum Levels of Magnesium in Children With Sickle Cell Anemia." The Journal of Pediatrics, vol. 140, no. 5, 2002, pp. 565-9.
Altura RA, Wang WC, Wynn L, et al. Hydroxyurea therapy associated with declining serum levels of magnesium in children with sickle cell anemia. J Pediatr. 2002;140(5):565-9.
Altura, R. A., Wang, W. C., Wynn, L., Altura, B. M., & Altura, B. T. (2002). Hydroxyurea therapy associated with declining serum levels of magnesium in children with sickle cell anemia. The Journal of Pediatrics, 140(5), pp. 565-9.
Altura RA, et al. Hydroxyurea Therapy Associated With Declining Serum Levels of Magnesium in Children With Sickle Cell Anemia. J Pediatr. 2002;140(5):565-9. PubMed PMID: 12032523.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Hydroxyurea therapy associated with declining serum levels of magnesium in children with sickle cell anemia. AU - Altura,Rachel A, AU - Wang,Winfred C, AU - Wynn,Lynn, AU - Altura,Burton M, AU - Altura,Bella T, PY - 2002/5/29/pubmed PY - 2002/7/5/medline PY - 2002/5/29/entrez SP - 565 EP - 9 JF - The Journal of pediatrics JO - J. Pediatr. VL - 140 IS - 5 N2 - OBJECTIVE: To obtain quantitative serum levels of total and ionized magnesium (Mg(2+)) in children with homozygous sickle cell anemia (SCA) undergoing therapy with hydroxyurea. STUDY DESIGN: Five children, ages 11 to 14 years with homozygous SCA, were enrolled in a dose-escalating trial of hydroxyurea over an 18-month period. Serum levels of total and ionized magnesium together with ionized K(+), Na(+), and Ca(2+) were measured before hydroxyurea and every 6 months during hydroxyurea therapy. RESULTS: Before treatment, 4 of the 5 patients had low or below-normal serum concentrations of Mg(2+) (normal range, 0.51-0.67 mmol/L). All 5 became Mg(2+)-deficient during hydroxyurea therapy, with no indication of recovery until after 12 to 18 months of drug administration (P <.05). Similar changes were noted for total magnesium concentrations. Mean serum levels of K(+), Na(+), and Ca(2+) remained consistently within normal ranges. CONCLUSIONS: These findings warrant a controlled study of the effects of magnesium supplementation in patients with SCA receiving hydroxyurea. Potentially, such therapy could alleviate or prevent vaso-occlusive crises. SN - 0022-3476 UR - https://www.unboundmedicine.com/medline/citation/12032523/Hydroxyurea_therapy_associated_with_declining_serum_levels_of_magnesium_in_children_with_sickle_cell_anemia_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0022-3476(02)00994-0 DB - PRIME DP - Unbound Medicine ER -